BioNTech SE
BNTX.O- Latest Trade
- trading higher149.1USD
- Change
- 0
- % Change
0.00%
- Day Range
- 142.10 - 153.80
- 52-Week Range
- 117.08 - 464.00
As of Jul 1 2022. Values delayed up to 15 minutes
- Previous Close
- 149.10
- Open
- 146.53
- Volume
- 2,495,583.00
- 3 Month Average Trading Volume
- 27.44
- Shares Out (Mil)
- 242.52
- Market Cap
- 34,503.87
- Forward P/E
- 3.91
- Dividend Yield
- -99,999.99
Key Statistics
2.47058824 mean rating - 17 analysts
- P/E Excl. Extra Items (TTM)
- 2.66
- Price To Sales (TTM)
- 1.42
- Price To Book (Quarterly)
- 2.07
- Price To Cash Flow (Per Share TTM)
- 2.55
- Total Debt/Total Equity (Quarterly)
- 1.17
- Long Term Debt/Equity (Quarterly)
- 0.98
- Return On Investment (TTM)
- 133.03
- Return On Equity (TTM)
- 104.99
2021 (millions USD)
About BioNTech SE
Company Information
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Address
An der Goldgrube 12MAINZ,
55131
Germany
Industry
Biotechnology & Drugs
Executive Leadership
- Helmut Jeggle
- Independent Chairman of the Supervisory Board
- Ugur Sahin
- Chief Executive Officer, Member of the Management Board
- Jens Holstein
- Chief Financial Officer
- Sierk Poetting
- Chief Operating Officer, Member of the Management Board
- Sean Marett
- Chief Compliance Officer, Chief Business Officer, Member of the Management Board
- Ryan Richardson
- Chief Strategy Officer, Member of the Management Board
- Oezlem Tuereci
- Chief Medical Office, Member of the Management Board
- Christoph Huber
- Independent Supervisory Board
- Michael Motschmann
- Independent Supervisory Board
- Ulrich Wandschneider
- Independent Supervisory Board
Latest News
- BusinessPfizer's vaccines head Kathrin Jansen to retire this year
Pfizer Inc's vaccines head Kathrin Jansen, who led the development of the U.S. drugmaker's COVID-19 shot, has decided to retire later this year.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,804.10 | -- |
| Copper | 682.95 | 1.61%Negative |
| Brent Crude Oil | 108.29 | 0.68%Negative |
| CBOT Soybeans | 1,662.50 | 0.75%Negative |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,785.38 | 0.88%Negative |
| Euro STOXX 50 | 3,454.86 | -- |
| FTSE 100 | 7,169.28 | 1.96%Negative |
| Nikkei 225 | 25,899.43 | 1.87%Negative |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes